M. Silverstein

@mabeky

Leukemia Department Administrator at MD Anderson Cancer Center

Houston, TX
Vrijeme pridruživanja: studeni 2010.

Tweetovi

Blokirali ste korisnika/cu @mabeky

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @mabeky

  1. proslijedio/la je Tweet

    Characteristically energetic lecture by from on this often misunderstood disease. IKZF1 inactivation and BCL-2 dependence inform this HCVAD + Ven backbone.

    Poništi
  2. proslijedio/la je Tweet

    Special shout out & 🙏 to Director of Fellowship Education Dr GGM & Co-Director for inviting me to speak at their successful & innovative Leukemia Fellows Lecture Series.Honored to present 101 to such a highly motivated & engaged group !

    , , i još njih 5
    Poništi
  3. proslijedio/la je Tweet
    prije 12 sati
    Poništi
  4. proslijedio/la je Tweet
    prije 10 sati

    Thank you so much Dr. Pemmeraju! We are very fortunate to have great teachers, mentors, clinicians and researchers like you at the heart of our fellowship program

    Prikaži ovu nit
    Poništi
  5. proslijedio/la je Tweet

    Very nice paper from Dr Bastidas Torres et al (The Netherlands 🇳🇱 + Italy 🇮🇹 collaboration) Whole‐genome analysis uncovers recurrent inactivation&aberrant cell adhesion in {Genes, Chromosomes and Cancer 2020 Wiley Online Library}

    Poništi
  6. proslijedio/la je Tweet

    Amazing lecture on by 👏🏻🤓 Very impressed by your enthusiastic and thoughtful way of presenting! 😁 And by the outstanding work to lead the approval of tagraxofusp, the first drug approved for this rare disease! 👍🏼🏆

    Poništi
  7. proslijedio/la je Tweet

    ➡️➡️➡️Hot off the presses! Use of CAR-Transduced Natural Killer Cells in -Positive Lymphoid Tumors | & {Liu E/Rezvani K et al Feb 6, 2020}

    Poništi
  8. proslijedio/la je Tweet
    prije 10 sati
    Poništi
  9. proslijedio/la je Tweet

    It's been remarkable to see the impact of novel treatment paradigms in acute myeloid in the last few years. Here's a great summary of the story, with a helpful table showing response rates and outcomes across studies:

    Poništi
  10. proslijedio/la je Tweet
    5. velj

    Another spectacular to appreciate this evening. A place of a moment to stop and appreciate the moment |

    Poništi
  11. proslijedio/la je Tweet
    5. velj
    Poništi
  12. proslijedio/la je Tweet
    4. velj

    Advances in the Treatment of Acute Myeloid : New Drugs and New Challenges | via | , Konopleva, , , Ravandi, DiNardo, and of .

    Poništi
  13. proslijedio/la je Tweet
    4. velj

    Prof. Nizar Tannir receiving the outstanding 2020 faculty mentor for his whole career mentoring amazing people like

    Poništi
  14. proslijedio/la je Tweet

    After a stage III diagnosis, Marc is now cancer-free after undergoing treatment with our Dr. Steven Kornblau. Read how Marc’s care team helped put him in remission.

    Poništi
  15. proslijedio/la je Tweet
    3. velj

    Happy National Women Physician’s Day to all of the women physicians ⁦⁩. So proud to work beside these intelligent, passionate and hard working women in our shared mission to cancer. Many thanks for your dedicated service.

    Poništi
  16. proslijedio/la je Tweet
    3. velj

    MD Anderson chronic lymphocytic leukemia specialist Alessandra Ferrajoli, MD joins Patient Power to discuss treating older CLL patients.

    Poništi
  17. proslijedio/la je Tweet
    3. velj
    Poništi
  18. proslijedio/la je Tweet
    3. velj
    Poništi
  19. proslijedio/la je Tweet
    30. sij

    We're ! Our Leukemia team is recruiting a Clinical , Outpatient - Center. Apply Online:

    Poništi
  20. proslijedio/la je Tweet
    22. sij

    Superb master class on Updates in CLL by the one&only today at Leukemia Grand Rounds. Updates on modern therapy in CLL including Ibrutinib + VEN updates by | see their paper

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·